Immuno-Oncology Strategic Insight – Multi-Indication And Market Size Analysis has recently announced the addition of a market study “ Immuno-Oncology Strategic Insight – Multi-Indication And Market Size Analysis , is a comparative analysis of the global market.

Immuno-Oncology Strategic Insight – Multi-Indication And Market Size Analysis


GlobalData estimates that the total IO market will be worth approximately $14 billion in 2019, rising to $34 billion by 2024 in the 7MM (US, France, Germany, Italy, Spain, UK, and Japan). The main drivers of this growth will come from immune checkpoint inhibitors, which will have sales of approximately $10 billion in 2019, rising to $24 billion by 2024. The highest-selling IO drugs by 2024 will be Opdivo and Keytruda, both PD-1 inhibitors, with sales of approximately $10 billion and $7 billion, respectively. This is because these two drugs will be first-to-market in many indications, leapfrogging competition such as Roches atezolizumab and AstraZenecas durvalumab.


Key Questions Answered

– Development of IO Products has increased significantly in the past three years. Which IO approaches will be the most commercially successful? Which early-stage IO approaches show the most promise?

– Novel combinations will differentiate late-to-market entrants. Which combinations are the most promising for each cancer type? What strategies are IO developers utilizing to differentiate themselves in this crowded market? What collaborations and deals are the most promising?

– NSCLC, melanoma, and myeloma will have the greatest contributions to the IO market in 2019 and 2024. Which diseases are going to be the biggest contributors to the IO market. Which IO product will be the most commercially successful in each disease? Which clinical and commercial strategies are IO developers pursuing in each disease?

Key Findings

– Opdivo will be the biggest selling IO drug by 2024, with approval forecast in seven indications

– Keytruda will be the second biggest selling IO drug by 2024, with approval forecast in eight indications

– NSCLC, melanoma, and myeloma will have the greatest contributions to the IO market in 2019 and 2024

– Novel combinations will allow late-to-market entrants such as durvalumab to achieve significant sales

Download The sample Copy Of This Report:


– Overview of IO approaches, including checkpoint inhibitors, cell therapies, peptide vaccines, oncolytic viruses, bi-specific antibodies and CAR-T therapies.

– Revenue by indications for major IO products in 2019 and 2024.

– Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the IO therapeutics market.

– Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.

– Analysis of the current and future market competition in the global IO therapeutics market. Insightful review of the key industry drivers, restraints and challenges. This include analysis of novel combinations and the role of biomarkers such as PD-L1

Reasons to buy

The report will enable you to –

– Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. Additionally a list of acquisition targets included in the pipeline product company list.

– Develop business strategies by understanding the trends shaping and driving the global multiple myeloma therapeutics market.

– Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global multiple myeloma therapeutics market in future.

– Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.

– Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

– Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Table of Contents

1 Table of Contents 8

1.1 List of Tables 14

1.2 List of Figures 15

2 Introduction 22

2.1 Catalyst 22

2.2 Related Reports 22

2.3 Upcoming Related Reports 22

3 IO Development 23

3.1 History of IO Development 23

3.2 Recent Timeline of IO Approvals 25

3.3 IO Product Classification 28

4 Technology and Product Overview 29

4.1 Checkpoint Modulators 29

4.1.1 Mechanism of Action 29

4.1.2 Clinical Overview 30

4.1.3 Opdivo (Nivolumab) 31

4.1.4 Keytruda (Pembrolizumab) 43

4.1.5 Atezolizumab 53

4.1.6 Durvalumab and Tremelimumab 62

4.1.7 Avelumab 72

4.1.8 Yervoy (Ipilimumab) 79

4.2 Cellular Immunotherapies 85

4.2.1 Dendritic Cell Therapies 85

4.2.2 CAR-T Therapies 87

4.2.3 Sales Estimate 88

4.2.4 SWOT Analysis 90

4.3 Cancer Vaccines 90

4.3.1 NeuVax 91

4.3.2 HyperAcute-Pancreas 92

4.3.3 ProstVac 92

4.3.4 Vigil 93

4.3.5 Other Late-Stage Vaccines 93

4.3.6 Sales Estimate 93

4.3.7 SWOT Analysis 95

4.4 Oncolytic Viruses 95

4.4.1 Imlygic (Talimogene laherparepvec) 95

4.4.2 ProstAtak 97

4.4.3 Other Late-Stage Oncolytic Viruses 97

4.4.4 Estimated Sales 98

About us is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are specially designed to save time and money for our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.

Read our latest Press Releases at


Mr. Nachiket

State Tower

90 State Street, Suite 700

Albany, NY 12207

Tel: +1-518-618-1030

USA: Canada Toll Free: 866-997-4948



Follow us on LinkedIn: